In December 2021, Svelte Medical Systems received U.S. FDA Premarket Approval (PMA P210014) for its SLENDER IDS® and DIRECT RX® sirolimus-eluting coronary stent systems, ACHieving the lowest 1-year clinically-driven target lesion revascularization (TLR) rate (1.5%) ever reported in a U.S. pivotal DES study. The company previously earned CE Mark for its sirolimus-eluting stents in 2015-2016 and secured Japan PMDA approval. On April 27, 2026, Advanced Bifurcation Systems Inc. (ABS) acquired all assets of Svelte Medical Systems, including its drug-eluting coronary stent portfolio, all intellectual property, and comprehensive U.S. and international regulatory approvals.
Company Profile (Updated April 2026)
Svelte Medical Systems, Inc. was a privately held medical device company headquartered in New Providence, New Jersey, USA. The company specialized in the design and development of highly deliverAble, low-profile balloon-expandable drug-eluting coronary stent (DES) systems. Svelte's innovative stent-on-a-wire and Rapid-exchange platforms were engineered to facilitate trans-radial intervention (TRI) and direct stenting, streamlining percutaneous coronary intervention (PCI) procedures while limiting complications and enhancing patient experience. On April 27, 2026, all company assets were acquired by Advanced Bifurcation Systems Inc.
Development History:
- 2012: Received conditional FDA approval to initiate the OPTIMIZE pivotal IDE study for the Svelte coronary stent system in the U.S.
- 2015: Earned CE Mark certification for the SLENDER Sirolimus-Eluting Coronary Stent system in Europe
- 2016: Received CE Mark certification for the DIRECT RX Sirolimus-Eluting Coronary Stent rapid-exchange system in Europe
- December 2021: Received U.S. FDA PMA approval (P210014) for the SLENDER IDS® and DIRECT RX® drug-eluting stent systems, enabling U.S. commercialization
- Post-2021: Continued U.S. commercial distribution under FDA PMA with post-approval study (PAS) requirements
- April 2026: All assets acquired by Advanced Bifurcation Systems Inc.
Core Mission: To develop extremely low-profile, highly deliverable drug-eluting stent systems that provide excellent early and long-term clinical outcomes in complex patient populations, while facilitating trans-radial intervention and direct stenting approaches.
2026 Acquisition by Advanced Bifurcation Systems
Asset Acquisition (April 27, 2026)
Transaction Overview:
- On April 27, 2026, Advanced Bifurcation Systems Inc. (ABS) announced the acquisition of all assets of Svelte Medical Systems, Inc.
- Acquired Portfolio: Drug-eluting coronary stents, all intellectual property, and related comprehensive U.S. and international regulatory approvals and filings
- Regulatory Assets: U.S. FDA Premarket Approval (PMA P210014); Europe CE Mark; Japan PMDA approval
- Strategic Significance: The acquisition placed ABS in a small group of select global companies possessing an FDA-approved drug-eluting coronary stent
- Synergy: Combined with ABS's bifurcation platform (FDA Breakthrough Device Designation), the Svelte portfolio accelerates ABS's development pathway and strengthens its presence in the global interventional cardiology market
Core Products: SLENDER IDS® and DIRECT RX®
SLENDER IDS® (Integrated Delivery System)
- Platform: An all-in-one integrated delivery system featuring stent-on-a-wire (SOAW) technology with Asahi guide wire technology
- Design: Balloon-expandable stent pre-mounted on a single-lumen fixed-wire implantation catheter
- Stent Material: Cobalt-chromium alloy (L-605)
- Stent Sizes: Diameters 2.5mm to 4.0mm; lengths 8mm to 28mm
- Guiding Catheter Compatibility: 5 French (Fr) compatible (minimum internal diameter 0.056 inches)
- Lesion Entry Profile: Formable radiopaque wire tip with 0.012-inch entry profile
- Indication: Improving coronary artery luminal diameter in patients with symptomatic heart disease due to atherosclerotic lesions ≤24 mm in length in native coronary arteries with reference vessel diameters ≥2.25 mm to ≤4.00 mm, using direct stenting or pre-dilatation techniques
- Drug: Sirolimus with a novel bioresorbable drug coating
- Key Advantage: World's lowest profile drug-eluting stent system, facilitating trans-radial intervention and general downsizing of access
DIRECT RX® (Rapid-Exchange Delivery System)
- Platform: A workhorse rapid-exchange delivery system
- Design: Incorporates the same specialized stent, bioresorbable drug coating, and balloon technologies as SLENDER IDS®
- Stent Sizes: Diameters 2.5mm to 4.0mm; lengths up to 34mm
- Indication: Improving coronary artery luminal diameter in patients with symptomatic heart disease due to atherosclerotic lesions ≤34 mm in length in native coronary arteries with reference vessel diameters ≥2.25 mm to ≤4.00 mm, using direct stenting or pre-dilatation techniques
- Key Advantage: Low-profile DES system designed to enhance direct stenting and trans-radial intervention
OPTIMIZE IDE Clinical Study
- Design: U.S. pivotal Investigational Device Exemption (IDE) study evaluating the SLENDER IDS® and DIRECT RX® systems
- Primary Endpoint: 1.5% clinically-driven target lesion revascularization (TLR) at 1 year, the lowest ever reported with an investigational DES in a U.S. pivotal study
- Direct Stenting: Undertaken in 30% of subjects, with 96% device success rates observed
- Trans-Radial Intervention (TRI): 80% of study subjects were treated via TRI
- Co-Principal Investigators: Dr. Dean Kereiakes, M.D., F.A.C.C. (President, The Christ Hospital Heart ＆ Vascular Institute, Cincinnati, Ohio; Clinical Professor of Medicine, The Ohio State University) and Dr. Sunil Rao, M.D., F.A.C.C. (Professor of Medicine, DUKe University, Durham, North Carolina)
- Investigator Statement: "Materially lower system and crossing profiles facilitate TRI, which, when combined with a direct stenting approach in appropriate clinical indications, streamline procedures, limit complications and enhance patient experience," said Dr. Sunil Rao
Regulatory Status
Global Regulatory Approvals
- U.S. FDA (December 2021): Premarket Approval (PMA) P210014 granted for SLENDER IDS® and DIRECT RX® Sirolimus-Eluting Coronary Stent Systems; indicated for direct stenting or pre-dilatation in native coronary arteries
- Europe CE Mark (2015-2016): SLENDER Sirolimus-Eluting system approved December 2015; DIRECT RX Sirolimus-Eluting rapid-exchange system approved October 2016
- Japan PMDA: Approved for commercial distribution
- Post-Approval Study (PAS): FDA-mandated PAS required following PMA approval, with periodic reporting obligations
- Current Status (April 2026): All assets, regulatory filings, and intellectual property transferred to Advanced Bifurcation Systems Inc.
Company Leadership (Pre-Acquisition)
Executive Team
Jack Darby - President ＆ Chief Executive Officer:
- Led the company through FDA PMA approval and U.S. commercial launch
Mark Kielek - Vice President, Quality Assurance ＆ Regulatory Affairs:
- Oversaw FDA PMA submission and regulatory compliance
- Primary regulatory contact for FDA communications (P210014)
Global Market Position and Competition
Market Landscape
Coronary Artery Disease Burden:
- Coronary artery disease remains a leADINg cause of morbidity and mortality worldwide
- Percutaneous coronary intervention (PCI) with drug-eluting stents is the standard of care for many patients with symptomatic coronary disease
- Trans-radial intervention (TRI) has become the dominant access approach globally, driving demand for lower-profile, more deliverable stent systems
Primary Competitors
- Abbott (Xience): Market-leading drug-eluting stent platform
- Medtronic (Resolute Onyx): Major DES competitor with comprehensive coronary portfolio
- Boston Scientific (Synergy): Bioabsorbable polymer DES technology
- Cordis (Cardinal Health): Established interventional cardiology portfolio
- BIOTRONIK (Orsiro): Thin-strut DES with bioabsorbable polymer
Competitive Advantages
- Lowest Profile: World's lowest profile drug-eluting stent system, enabling 5Fr guiding catheter compatibility and facilitating trans-radial intervention
- Superior Clinical Outcomes: 1.5% 1-year TLR in OPTIMIZE study, the lowest reported in a U.S. pivotal DES trial
- Direct Stenting Enabled: System design supports direct stenting in appropriate lesions, reducing procedure time and contrast use
- Novel Drug Coating: Bioresorbable drug carrier technology distinct from traditional durable polymer coatings
- Integrated Delivery Innovation: SLENDER IDS® stent-on-a-wire design eliminates the need for separate guidewire exchange
- Global Regulatory Footprint: FDA PMA, CE Mark, and Japan PMDA approvals provided immediate worldwide market access
2026 Outlook Under Advanced Bifurcation Systems
Strategic Integration
- Portfolio Expansion: ABS now holds an FDA-approved drug-eluting stent portfolio alongside its bifurcation platform
- Regulatory Leverage: Svelte's PMA, CE Mark, and PMDA approvals provide ABS with established regulatory pathways and commercial infrastructure
- Global Market Entry: The acquired portfolio positions ABS for immediate commercial presence in the U.S., European, and Japanese interventional cardiology markets
- R＆D Synergy: Svelte's stent and coating technologies may be integrated with ABS's bifurcation delivery platform to accelerate development of next-generation bifurcation-specific drug-eluting solutions
Contact Information
Former Headquarters
Address: 675 Central Avenue, Suite 2, New Providence, New Jersey 07974, USA
Phone: +1-908-665-0001
Former Website: www.sveltemedical.com
Current Status
Acquisition: All assets acquired by Advanced Bifurcation Systems Inc. on April 27, 2026
Acquirer Website: www.advancedbifurcation.com
Acquirer Email: info@advancedbifurcation.com
Keywords: Svelte Medical Systems, SLENDER IDS, DIRECT RX, drug-eluting stent, DES, coronary stent, sirolimus, bioresorbable polymer, cobalt-chromium, trans-radial intervention, TRI, direct stenting, FDA PMA, CE Mark, PMDA, OPTIMIZE trial, New Providence, New Jersey, coronary artery disease, PCI, low profile, integrated delivery system, rapid exchange, Advanced Bifurcation Systems, acquisition 2026, Jack Darby, Mark Kielek, Dean Kereiakes, Sunil Rao
